Skip to main content
Premium Trial:

Request an Annual Quote

Myriad to Buy Back $200M in Shares

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Monday that its board has approved a new $200 million stock repurchase program.

The board had previously approved a $100 million stock buyback program in March.

Repurchases under the new program will be made through open market or privately negotiated purchases. The amount and timing of the repurchases will depend on a number of factors including business and market conditions, trading restrictions, acquisition activity, and stock price, the Salt Lake City company said.

As of June 30, Myriad had more than $417 million in cash, cash equivalents, and marketable securities.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.